STOCK TITAN

Polyrizon raises $4.0M in units and warrants

Polyrizon Ltd. (PLRZ) completed a registered direct offering and concurrent private placement with a single institutional investor, raising aggregate gross proceeds of approximately $4.0 million.

(Neutral)
(Neutral)
Form Type
6-K

Rhea-AI Filing Summary

Polyrizon Ltd. (PLRZ) completed a registered direct offering and concurrent private placement with a single institutional investor, raising aggregate gross proceeds of approximately $4.0 million.

The transactions involved the sale of 333,333 Units (or Pre-Funded Units), each consisting of one Ordinary Share (or one Pre-Funded Warrant) and one Common Warrant, at $12.00 per Unit (or $11.99999 per Pre-Funded Unit). Polyrizon issued 232,500 Ordinary Shares and 30,000 Pre-Funded Warrants in the registered direct component and 70,833 PIPE Pre-Funded Warrants and 333,333 PIPE Common Warrants in the private placement. The Pre-Funded Warrants are immediately exercisable at $0.00001 per share (subject, for unregistered PIPE Pre-Funded Warrants, to registration), and the Common Warrants have a $12.00 per share exercise price. Polyrizon expects to use the net proceeds for general corporate purposes and working capital.

Positive

  • None.

Negative

  • None.

Filing Explained

The September 4, 2026 filing adds that, although the $4.0 million offering had closed, the private-placement securities were unregistered and Polyrizon agreed to file resale registration statements covering the shares underlying the warrants.

Aggregate gross proceeds $4.0 million Gross proceeds from the registered direct offering and concurrent private placement
Units (or Pre-Funded Units) sold 333,333 Units Each Unit or Pre-Funded Unit consists of one Ordinary Share or Pre-Funded Warrant and one Common Warrant
Unit offering price $12.00 per Unit Combined offering price per Unit in the transaction
Pre-Funded Unit price $11.99999 per Pre-Funded Unit Equals Unit price minus $0.00001 Pre-Funded Warrant exercise price
Ordinary Shares issued 232,500 shares Ordinary Shares issued in the registered direct offering component
Pre-Funded Warrants issued in registered direct 30,000 warrants Pre-Funded Warrants issued in the registered direct offering
PIPE Pre-Funded Warrants 70,833 warrants Pre-Funded Warrants issued in the concurrent private placement
PIPE Common Warrants 333,333 warrants Common Warrants issued in the concurrent private placement with a $12.00 exercise price
registered direct offering financial
"announced the closing of its previously announced registered direct offering"
A registered direct offering is a way for a company to sell new shares of its stock directly to select investors with regulatory approval. This method allows the company to raise funds quickly and efficiently without needing a public auction, similar to offering exclusive access to a limited number of buyers. For investors, it often provides an opportunity to purchase shares at a favorable price, while giving the company immediate access to capital.
private placement financial
"closing of its previously announced registered direct offering and concurrent private placement"
A private placement is a sale of securities directly to a selected group of investors, typically institutions or accredited investors, instead of through a public offering. It lets a company raise money faster and with fewer regulatory steps; for existing shareholders it matters because the newly issued shares, often sold at a discount, increase the share count and can dilute their ownership.
Pre-Funded Warrants financial
"issued 232,500 Ordinary Shares and 30,000 Pre-Funded Warrants"
Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.
Common Warrants financial
"333,333 PIPE Common Warrants"
A common warrant is a tradable instrument that gives its holder the right to buy a company’s common shares at a fixed price within a set time period, similar to a coupon that can be redeemed later to purchase stock. Investors care because exercising warrants can boost potential gains if the stock rises, but it can also dilute existing shareholders by increasing the number of shares outstanding, which can lower per-share value.
shelf registration statement regulatory
"pursuant to an effective shelf registration statement on Form F-3"
A shelf registration statement is a document a company files with regulators that allows it to sell shares or bonds quickly when it’s a good time to raise money. It’s like having a pre-approved plan ready so the company can act fast without going through lengthy paperwork each time they want to sell, making fundraising more flexible.
registration rights agreement regulatory
"Pursuant to a registration rights agreement with the investors"
A registration rights agreement is a contract that gives investors the option to have their ownership stakes officially registered with the government, making it easier to sell their shares later. This agreement matters because it provides investors with a clearer path to cash out their investments if they choose, offering more liquidity and confidence in their ability to sell their holdings when desired.
Offering Type shelf
Use of Proceeds Net proceeds, together with existing cash, are expected to be used for general corporate purposes and working capital.

FAQ

What capital did Polyrizon Ltd. (PLRZ) raise in the September 2026 offering?

Polyrizon raised approximately $4.0 million in aggregate gross proceeds from a registered direct offering and concurrent private placement with a single institutional investor, issuing Units composed of Ordinary Shares or pre-funded warrants plus Common Warrants.

How many Units and securities did PLRZ issue in the transaction?

Polyrizon sold 333,333 Units (or Pre-Funded Units), issuing 232,500 Ordinary Shares, 30,000 Pre-Funded Warrants, 70,833 PIPE Pre-Funded Warrants, and 333,333 PIPE Common Warrants to a single institutional investor.

What were the prices and exercise terms of Polyrizon’s September 2026 Units and warrants?

Each Unit was priced at $12.00, and each Pre-Funded Unit at $11.99999, reflecting a $0.00001 exercise price per Pre-Funded Warrant. The Common Warrants issued in the transaction have an exercise price of $12.00 per Ordinary Share.

How does Polyrizon Ltd. (PLRZ) plan to use the proceeds from this offering?

Polyrizon states that it expects to use the net proceeds from the registered direct offering and private placement, together with existing cash, for general corporate purposes and working capital.

Were the Polyrizon (PLRZ) securities sold under a shelf registration statement?

Yes. The registered direct offering was conducted under an effective Form F-3 shelf registration statement No. 333-291368, which was declared effective on December 3, 2025. The concurrent private placement securities were sold in a transaction not involving a public offering.

What registration rights did investors receive in Polyrizon’s private placement?

Under a registration rights agreement, Polyrizon agreed to file one or more registration statements with the SEC to cover the resale of the Ordinary Shares and the shares issuable upon exercise of the pre-funded warrants and warrants sold in the private placement.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 6-K

 

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

 

For the month of September 2026

 

Commission file number: 001-42375

 

Polyrizon Ltd.

(Translation of registrant’s name into English)

 

8 Ha-Pnina Street

Raanana, 4321545, Israel

(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F ☒       Form 40-F 

 

 

 

 

 

CONTENTS

 

Attached hereto and incorporated herein is the Registrant’s press release issued on September 4, 2026, titled “Polyrizon Ltd. Announces Closing of $4.0 Million Registered Direct Offering and Private Placement.”

 

The first paragraph of the press release attached to this Report of Foreign Private Issuer on Form 6-K as Exhibit 99.1 is incorporated by reference into the Registrant’s Registration Statements on Form S-8 (File No. 333-284410 and 333-288923) and Form F-3 (333-291368), filed with the Securities and Exchange Commission, to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

 

1

 

 

EXHIBIT INDEX

 

Exhibit No.    
99.1   Press release titled: “Polyrizon Ltd. Announces Closing of $4.0 Million Registered Direct Offering and Private Placement”

 

2

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  Polyrizon Ltd.
   
Date: September 4, 2026 By: /s/ Tomer Izraeli
  Name:  Tomer Izraeli
  Title: Chief Executive Officer

 

3

Exhibit 99.1

 

Polyrizon Ltd. Announces Closing of $4.0 Million Registered Direct Offering and Private Placement

 

RAANANA, ISRAEL, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (NASDAQ: PLRZ) (the “Company”), a development-stage biotech company specializing in the development of innovative intranasal hydrogels, today announced the closing of its previously announced registered direct offering and concurrent private placement. The Company issued to a single institutional investor Ordinary Shares and pre-funded warrants in a registered direct offering. In a concurrent private placement, the Company also issued to the same investor pre-funded and investor warrants. Aggregate gross proceeds to the Company from both transactions were approximately $4.0 million.

 

The transactions consisted of the sale of 333,333 Units (or Pre-Funded Units), each consisting of one (1) Ordinary Share (or one (1) Pre-Funded Warrant to purchase one (1) Ordinary Share) and one (1) Common Warrant to purchase one (1) Ordinary Share, at a combined offering price of $12.00 per Unit (or $11.99999 per Pre-Funded Unit, equal to the offering price per Unit minus an exercise price of $0.00001 per Pre-Funded Warrant). In the registered direct offering, the Company issued 232,500 Ordinary Shares and 30,000 Pre-Funded Warrants. In the concurrent private placement, the Company issued 70,833 PIPE Pre-Funded Warrants and 333,333 PIPE Common Warrants. The Pre-Funded Warrants are immediately exercisable (subject to registration for unregistered PIPE Pre-Funded Warrants) and may be exercised at any time until exercised in full. The Common Warrants have an exercise price of $12.00 per share.

 

The transactions closed on September 4, 2026. The Company expects to use the net proceeds from the offerings, together with its existing cash, for general corporate purposes and working capital.

 

Aegis Capital Corp. acted as exclusive placement agent for the offerings. Meitar | Law Offices acted Israeli counsel to the Company. Kaufman & Canoles, P.C. acted counsel to Aegis Capital Corp.

 

The registered direct offering was made pursuant to an effective shelf registration statement on Form F-3 (No. 333-291368) previously filed with the U.S. Securities and Exchange Commission (SEC) and declared effective by the SEC on December 3, 2025. A final prospectus supplement and accompanying prospectus describing the terms of the proposed offering will be filed with the SEC and will be available on the SEC’s website located at www.sec.gov. Electronic copies of the final prospectus supplement and the accompanying prospectus may be obtained, when available, by contacting Aegis Capital Corp., Attention: Syndicate Department, 1345 Avenue of the Americas, 27th floor, New York, NY 10105, by email at syndicate@aegiscap.com, or by telephone at +1 (212) 813-1010.

 

The offer and sale of the securities in the private placement were made in a transaction not involving a public offering and have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), or applicable state securities laws. Accordingly, the securities may not be reoffered or resold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws. The securities were offered only to accredited investors. Pursuant to a registration rights agreement with the investors, the Company has agreed to file one or more registration statements with the SEC covering the resale of the Ordinary Shares and the Shares issuable upon exercise of the pre-funded warrants and warrants.

 

 

 

This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

 

About Polyrizon Ltd.

 

Polyrizon is a development stage biotech company specializing in the development of innovative medical device hydrogels delivered in the form of nasal sprays, which form a thin hydrogel-based shield containment barrier in the nasal cavity that can provide a barrier against viruses and allergens from contacting the nasal epithelial tissue. Polyrizon’s proprietary Capture and Contain TM, or C&C, hydrogel technology, comprised of a mixture of naturally occurring building blocks, is delivered in the form of nasal sprays, and potentially functions as a “biological mask” with a thin shield containment barrier in the nasal cavity. Polyrizon is further developing certain aspects of its C&C hydrogel technology such as the bioadhesion and prolonged retention at the nasal deposition site for intranasal delivery of drugs. Polyrizon refers to its additional technology, which is in an earlier stage of pre-clinical development, that is focused on nasal delivery of active pharmaceutical ingredients, or APIs, as Trap and Target ™, or T&T. For more information, please visit https://polyrizon-biotech.com.

 

Forward-Looking Statements

 

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses the intended use of proceeds from the offering. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s annual report filed with the SEC on March 25, 2026 and subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Polyrizon is not responsible for the contents of third-party websites.

 

Michal Efraty
Investor Relations
IR@polyrizon-biotech.com

 

Filing Exhibits & Attachments

1 document